Alnylam Pharmaceuticals Inc
(XTER:DUL)
€
278
-17.1 (-5.79%)
Market Cap: 33.77 Bil
Enterprise Value: 32.25 Bil
PE Ratio: 81.63
PB Ratio: 37.07
GF Score: 74/100 Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2022 / 12:00PM GMT
Release Date Price:
€138.7
(-0.04%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
Great. My name is Gena Wang. I'm SMID-cap biotech analyst at the Barclays. Welcome to our first in-person Global Healthcare Conference post pandemic. I hope pandemic is ending. It's really nice to see everyone in person and I would like to also thank all the participants, investors, companies and especially our event team and the corporate access team who made this event possible.
With that, I would like to introduce our first presenting company, Alnylam. Jeff Poulton, Chief Financial Officer, will be with us today. Thank you very much, Jeff.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Thank you. Nice to be here.
Huidong Wang;Jeffrey V. Poulton
Barclays Bank PLC, Research Division - Research Analyst;Alnylam
Yes. So before I start with any questions, do you want to just highlight very high-level overview of Alnylam, how much has been achieved in the past several decades now?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot